- Home
- ACCS vs NEPH Comparison
ACCS vs NEPH Comparison
Compare ACCS & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | NEPH |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Publishing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 31.0M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | ACCS | NEPH |
|---|---|---|
| Price | $7.86 | $2.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $6.00 |
| AVG Volume (30 Days) | 6.5K | ★ 20.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | $7.40 | $11.24 |
| Revenue Next Year | $8.75 | $11.58 |
| P/E Ratio | ★ N/A | $26.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $6.51 | $1.78 |
| 52 Week High | $13.35 | $6.42 |
Technical Indicators
Market Signals| Indicator | ACCS | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 46.76 |
| Support Level | $7.82 | $2.79 |
| Resistance Level | $9.16 | $3.18 |
| Average True Range (ATR) | 0.31 | 0.20 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 18.38 | 64.48 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.